Our September sale is now live until 30th September 2021! Apply a 15% discount to your cart in Store using promotional code: EQLYSEP21

STADA Arzneimittel AG in Consumer Health

December 2020

STADA has continued to grow strongly during challenging times and, despite the difficult operating environment created by the coronavirus pandemic, which has reduced growth rates across most of the consumer health industry, the company doubled its revenue in 2020, following several acquisitions during the year. STADA’s recent rapid growth, with an aggressive acquisition strategy and ongoing brand awareness activities, creates optimism for the company’s performance in the coming years.

USD 570
Request More Information


Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).


Euromonitor International's report on STADA Arzneimittel AG delivers a detailed strategic analysis of the company's business, examining its performance in the Consumer Health market and the global economy. Company and market share data provide a detailed look at the financial position of STADA Arzneimittel AG, while in-depth qualitative analysis will help you understand the brand strategy and growth prospects of STADA Arzneimittel AG.

This report examines:

  • Company share by region and sector
  • Brand portfolio
  • New product developments
  • Marketing and distribution strategies

A detailed SWPT analysis of STADA Arzneimittel AG provides strategic intelligence on:

  • Strengths and weaknesses
  • Category and country opportunities for growth
  • Challenges and threats from current competition and future prospects
  • Global and regional market positions

Research you can trust:

Euromonitor International's company profile reports are written by our Consumer Health research team, a dedicated group of analysts that knows the industry inside and out. Buy this report to inform your planning, strategy, marketing, sales and competitor intelligence functions.

Scope of the Report



Executive summary

State of Play

Top companies at a glance
STADA Arzneimittel AG’s global footprint
Company overview
STADA’s growth is largely driven by M&A

Exposure to Future Growth

Western Europe set to be the main contributor to future growth
Impact of COVID-19 on STADA Arzneimittel AG

Competitive Positioning

STADA expected to see positive outlook
Dermatologicals and CCA in Germany has the greatest competitive overlap
STADA has a strong position in dermatologicals in Europe…
…. and seeks to gain positions in other categories
German brand portfolio is different from that in other markets
Grippostad and Nizoral/Terzolin have a global presence

Cough, Cold and Allergy (Hay Fever) Remedies

Western Europe is STADA’s largest market for CCAs
STADA’s CCA portfolio varies globally
Germany and UK forecast to see the biggest impact on STADA’s portfolio


Eastern Europe leads STADA’s analgesics sales
STADA’s analgesics portfolio is very polarised in most markets
Analgesics has high growth potential among STADA’s portfolio

Key Findings

Key findings


Projected company s ales: FAQs (1)
Projected company s ales: FAQs (2)

Why buy this report:

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions


If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page